PTPN2 and chronic myelogenous leukemia, BCR-ABL1 positive: To further evaluate the proteasome-inhibiting effects of PtPT, bone marrow cells from 10 patients with CML (3 patients are IM resistant) were treated ex vivo with escalating doses of PtPT.